---
title: "Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Definition and etiology"
description: "Formulary evidence on Darovasertib (IDE196, LXS196) in First-line metastatic uveal melanoma, in combination with crizotinib: Definition and etiology. Topics: Definition of uveal melanoma and its sites of origin, Distribution of primary tumors by uveal site, Cell of origin and relation to cutaneous melanoma, Ultraviolet light exposure and incidence trend, and 5 further topics. 9 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description/definition-and-etiology"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Definition and etiology

<a id="heading-2.2.1.1"></a>

## 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

### Definition of uveal melanoma and its sites of origin

> “Melanoma of the uveal tract (iris, ciliary body, and choroid) is rare, but it is the most common primary intraocular malignancy in adults.”
> “Uveal melanomas can arise in the anterior (iris) or the posterior (ciliary body or choroid) uveal tract.”
> “Most uveal tract melanomas originate in the choroid. The ciliary body is a less common site of origin, and the iris is the least common.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.1-2"></a>

### Distribution of primary tumors by uveal site

> “UM appears as a pigmented or achromic mass arising from the choroid (90%), the ciliary body (6%) or the iris (4%)”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.1-3"></a>

### Cell of origin and relation to cutaneous melanoma

> “Uveal melanoma (UM), which arises from melanocytes resident in the uveal tract, is the second most common melanoma subtype after cutaneous melanoma (CM)”

Source: [Robertson et al. (2017)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5619925/)

<a id="topic-2.2.1.1-4"></a>

### Ultraviolet light exposure and incidence trend

> “Unlike cutaneous melanoma, the incidence of UM has remained stable over time and is not linked to ultraviolet light exposure, except iris melanoma.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

> “In view of these susceptibility factors, numerous observational studies have explored the relationship between sunlight exposure and risk of uveal melanoma. These studies have found only weak associations or yielded contradictory results.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

<a id="topic-2.2.1.1-5"></a>

### Race, ethnicity, and iris color as risk factors

> “UM affects non-Hispanic white patients 18 times more frequently than black patients and 15 times more than Asian patients.”
> “Grey/blue-eyed coloured irises are at higher risk than brown-eyed coloured irises.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.1-6"></a>

### Familial uveal melanoma and germline BAP1 and MBD4 variants

> “About 2%-5% of UMs are considered familial and are mainly associated with germline mutations in the tumour-suppressor gene BAP1 and less frequently with an MBD4 pathologic variant.”
> “Germline mutations in BAP1 have been identified as being responsible for the BAP1 tumour predisposition syndrome (BAP1-TPDS), which is associated with UM, mesothelioma, cutaneous melanoma and renal cell carcinoma.”

Source: [Piperno-Neumann et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13131131/)

<a id="topic-2.2.1.1-7"></a>

### Risk factors: fair skin, light eye color, ocular melanocytosis, and BAP1 tumor predisposition syndrome

> “Risk factors include fair skin, light-coloured eyes, congenital ocular melanocytosis, ocular melanocytoma and the BAP1-tumour predisposition syndrome.”

Source: [Jager et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32273508/)

<a id="topic-2.2.1.1-8"></a>

### Nevus of Ota as a risk factor

> “The nevus of Ota, a subtle intradermal proliferation of melanocytes resulting in bluish-gray hyperpigmentation in the sclera and periorbital dermis, is a risk factor for uveal melanoma.”

Source: [Van Raamsdonk et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3107972/)

<a id="topic-2.2.1.1-9"></a>

### Progression of choroidal nevi to melanoma

> “In a large, retrospective, single-center series of 2,514 consecutive patients with choroidal nevi, the progression rate to melanoma was 8.6% at 5 years, 12.8% at 10 years, and 17.3% at 15 years.”

Source: [National Cancer Institute intraocular melanoma treatment PDQ (2025)](https://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq)

## Related pages
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Terms and abbreviations](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/terms-and-abbreviations.md)
- [Darovasertib (IDE196): First-line metastatic uveal melanoma, in combination with crizotinib](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/executive-summary.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Product information and disease description](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/product-information-and-disease-description.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Clinical evidence](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/clinical-evidence.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: Economic information and modeling report](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/economics.md)
- [Darovasertib (IDE196) in First-line metastatic uveal melanoma, in combination with crizotinib: References](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references) · [Markdown](https://www.evicenter.com/drugs/darovasertib--first-line-metastatic-uveal-melanoma-in-combination-with-crizotinib/references.md)
